In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Inovio Pharmaceuticals (INO – Research Report), with a price target of $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roy Buchanan’s rating is based on several promising aspects of Inovio Pharmaceuticals’ recent developments. The company’s DMAb platform has shown impressive results in its Phase 1 trial, particularly in the production of antibodies that protect against COVID-19. The durability of these antibodies, lasting up to 72 weeks, highlights the potential of Inovio’s technology to extend beyond just antibodies to other therapeutic proteins. This long-lasting expression is a significant factor in Buchanan’s positive outlook.
Furthermore, the trial demonstrated favorable pharmacokinetics and safety profiles, with no concerning adverse events or anti-drug antibodies detected. The cost and logistical advantages of DNA-based therapies over traditional monoclonal antibodies add to the platform’s appeal. Buchanan believes that with further development, Inovio’s technology could become a viable alternative in various therapeutic settings, justifying the Buy rating and the $18 price target.